Ovid and Take­da cre­ate a one-team strat­e­gy to steer a neu­ro drug to the world

Je­re­my Levin’s team at Ovid Ther­a­peu­tics has been scour­ing the globe for new drugs to treat or­phan brain dis­eases. And af­ter spend­ing a year in dis­cus­sions with a fast-chang­ing Take­da, the lit­tle biotech and large phar­ma or­ga­ni­za­tion are bond­ing on a tight­ly knit part­ner­ship aimed at joint­ly ad­vanc­ing an ear­ly-stage pro­gram for rare epilep­tic en­cephalopathies that will see Ovid build a new group op­er­a­tion in Cam­bridge, MA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.